Aurobindo Pharma

Equities

AUROPHARMA

INE406A01037

Pharmaceuticals

Market Closed - NSE India S.E. 08:01:59 2024-03-28 am EDT 5-day change 1st Jan Change
1,089 INR +1.72% Intraday chart for Aurobindo Pharma +7.03% +0.44%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024 CI
Indian shares set to track Asian peers higher, eye on Fed meet RE
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray MT
Aurobindo Pharma Limited Receives Final Approval from the US Food & Drug Administration CI
Aurobindo Pharma Arm Restarts Distribution of Aseptic Products from Unit III MT
APL Healthcare Limited Subsidiary of Aurobindo Pharma Limited Announces Unit Inspection Team of World Health Organization Conducts an Inspection at the Unit IV CI
Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer CI
Aurobindo Pharma Limited Receives USFDA Approval for Fingolimod Capsules, 0.5 Mg CI
Indian shares set to rise on strong domestic growth, in-line US inflation data RE
US FDA Completes Inspection of Aurobindo Pharma's Injectibles Unit MT
US FDA Clears Aurobindo Pharma Arm's Manufacturing Unit in Telangana, India MT
INDIA STOCKS-Auto stocks drive Indian shares higher RE
Aurobindo Pharma Limited Receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg CI
Aurobindo Pharma Clocks Gains in Fiscal Q3 Consolidated Net Profit MT
INDIA STOCKS-Energy shares drag India's blue-chip stocks; small, mid-caps slide RE
Transcript : Aurobindo Pharma Limited, Q3 2024 Earnings Call, Feb 12, 2024
Aurobindo Pharma Limited Approves the Resignation of Dr.(Mrs.) Avnit Bimal Singh as an Independent Director CI
Aurobindo Pharma Limited Approves Second Interim Dividend, Payable on or Before March 4, 2024 CI
India's Glenmark Life Sciences posts Q3 profit rise; strong orderbook ahead, says CEO RE
Aurobindo Pharma's Telangana Facility Receives 'Voluntary Action Indicated' Classification from US FDA MT
Aurobindo Pharma Unit Gets US FDA's Final Approval for Generic Anfi-Fungal Drug MT
Aurobindo Gets 10 Observations from US FDA for Subsidiary's New Jersey Injectable Plant MT
Aurobindo Pharma Arm Gets US FDA's Final Approval for Generic Asthma Maintenance Treatment MT
Aurobindo Pharma Gets Final US FDA Nod for Darunavir Tablets MT
Aurobindo Pharma Receives USFDA Approval for Darunavir Tablets, 600 mg and 800 mg CI
Chart Aurobindo Pharma
More charts
Aurobindo Pharma specializes in the research, development, manufacturing and marketing of active pharmaceutical ingredients and generic pharmaceuticals. The group's activity is organized around 2 product families : - generic drugs: for the treatment of neurological, cardiovascular, viral, gastroenterological, ophthalmologic and chronic diseases; - active pharmaceutical ingredients. At the end of March 2018, the group operated 23 production sites in India (19), the United States (3) and Brazil. Net sales are distributed geographically as follows: India (12%), the United States (46.5%), Europe (31.2%) and other (10.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
1,089 INR
Average target price
1,166 INR
Spread / Average Target
+7.12%
Consensus
  1. Stock
  2. Equities
  3. Stock Aurobindo Pharma - NSE India S.E.
  4. News Aurobindo Pharma
  5. Aurobindo Pharma Completes Acquisition of Majority Stake in GLS Pharma